Non-arteritic anterior ischemic optic neuropathy is not listed as a known adverse drug reaction in the summary of product characteristics (SmPC) for the marketed formulations of semaglutide (Ozempic and Rybelsus for type 2 diabetes and Wegovy for weight management) as per the approved labels.
Choose lightweight, water-based peptide serums rather than heavy creams
Wear PPE including gloves, lab coat, and protective eyewear Handle compounds within approved laboratory workspaces Avoid inhalation, ingestion, or direct contact Dispose of materials according to institutional chemical waste procedures Maintain proper labeling and documentation for stored research compounds These practices support safe laboratory operation and regulatory compliance
It is not suitable for consumption by humans, nor for medical, veterinary, or household purposes
References Badenhorst, T., Svirskis, D., Wilsher, T., & O'Sullivan, J